Home › Kanser sa Ovary › California › San Francisco
Pag-aaral pangklinika para sa Kanser sa Ovary sa San Francisco, CA
19 pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng San Francisco (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Research Site, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Nagre-recruit
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Nagre-recruitPhase 2
- California Pacific Medical Center - Van Ness Campus /ID# 275329, San Francisco
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
- UCSF Medical Center at Mission Bay ( Site 0013), San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Nagre-recruitPhase 1
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- UCSF Medical Center-Mission Bay, San Francisco
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Nagre-recruitPhase 3
- Site 0115, San Francisco
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
- Kaiser Permanente-San Francisco, San Francisco
- UCSF Medical Center-Mission Bay, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of California San Francisco Cancer Center, San Francisco
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Nagre-recruitPhase 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Nagre-recruitPhase 2
- 014, San Francisco
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 2
- University of California San Francisco, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Nagre-recruit
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, San Francisco
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY69 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
Iba pang pag-aaral sa San Francisco
- Kanser sa Prostate45 pag-aaral
- Kanser sa Suso43 pag-aaral
- Non-Small Cell Lung Cancer36 pag-aaral
- Kanser (lahat ng uri)35 pag-aaral
- Pagkabigo ng Puso29 pag-aaral
- Metastatic Cancer28 pag-aaral
- Kanser sa Baga22 pag-aaral
- Melanoma22 pag-aaral
- Kanser sa Pancreas20 pag-aaral
- Colorectal Cancer18 pag-aaral
- Sakit sa Puso at Ugat ng Dugo18 pag-aaral
- Glioblastoma17 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.